Copyright
©2007 Baishideng Publishing Group Co.
World J Gastroenterol. Feb 14, 2007; 13(6): 830-836
Published online Feb 14, 2007. doi: 10.3748/wjg.v13.i6.830
Published online Feb 14, 2007. doi: 10.3748/wjg.v13.i6.830
Phase | Drugs | Company |
Phase III | Emtricitabine (FTC) | Gilead (California, USA) |
Tenofovir DF | Gilead (California, USA) | |
Telbivudine (L-dT) | Idenix (Massachusetts, USA) | |
Clevudine (L-FMAU) | Gilead/Triangle (California, USA) | |
Phase II | Elvucitabine (β-L-Fd4C) | Achillion (Connecticut, USA) |
Valtorcitabine (val-L-dC) | Idenix (Massachusetts, USA) | |
Amdoxovir (DAPD) | Triangle (California, USA) | |
Racivir [(+/-)-FTC] | Pharmasset (New Jersey, USA) | |
LB80380 | LG Life Sciences (Seoul, Korea) | |
Phase I | Alamifovir (purine nucleoside analogue) | Lilly/Mitsubishi (Indiana, USA/Osaka, Japan) |
MIV 210 (FLG prodrug) | Medivir/GSK (Huddinge, Sweden/Brentford, UK) | |
Hepavir B (PMEA prodrug) | Ribapharm (California, USA) | |
Pre-clinical | β-L-FddC | Biochem/GSK (Sante-Foy, Canada/Brentford, UK) |
6- [2- (phosphonomethoxy) alkoxy]-2, 4-diaminopyrimidines | Rega Institute for Medical Research, K.U.Leuven (Leuven, Belgium) | |
2-benzenesulfonylalkyl-5-substituted-sulfanyl-[1, 3, 4]-oxadiazoles | National University of Singapore (Singapore) |
- Citation: Wu GY, Chen HS. Novel approaches towards conquering hepatitis B virus infection. World J Gastroenterol 2007; 13(6): 830-836
- URL: https://www.wjgnet.com/1007-9327/full/v13/i6/830.htm
- DOI: https://dx.doi.org/10.3748/wjg.v13.i6.830